text:
This is such a cute pattern! However, the CUTEST thing about this whole project was discovering Suki using it as a sleep sack upon my return from fetching the camera in the den...
This is her reluctantly crawling out after about 20 minutes...
That's great Mill!
OMG! I don't know which is more cute, the dog or the hat. Your work the hat is great!
To sit with a dog on a hillside on a glorious afternoon is to be back in Eden, where doing nothing was not boring-it was peace.
~Milan Kundera
The best Fish Hat I've seen yet, even without the dog! Nice work
This is too cute. She definitely knows quality sleeping arrangements. As to sleeping all the time...did she take lessons from the kittehs? -- Books, knitting, cats, fountain pens...Life is Good.
Oh Mill .... this is just to cute. She is adorable. We have a chiuhuahua from hell. He is adorable and loving so long as you are known to him but strangers beware. His name is Chester and he has never bitten anyone but he certainly doesn't make them welcome. He got expelled from puuppy training school. lol
That's so funny! I know of many chis that have social issues with folks outside of their inner circle. Suki is the opposite. She's very non-chi like to tell you the truth. She's super friendly with everyone she meets, I've heard her bark like 8 times in 6 years and she has the activity level of an old lab. I often have to carry her back to the house on walks, because she will stop after 4 or 5 blocks, lie down and give me this look like, "Ok, I'm done" and WILL NOT take another step no matter what I do. I think she was a Jewish grandmother in her past life.
Just too darn cute!
This is so funny!! I really like the hat.... and what an adorable dog.
That is priceless. Nice touch up on the photo, haha!
It is indeed a delightful pattern! How did you make the fish eyes?
Thanks Willy! The directions
are written out under my "notes." Just follow the link. Yours is actually one of my favorites on Rav and I love the name of yours! I like cool project names!
P.S. I just friended you on Rav. I can't believe we weren't friends yet!
this is just too adorable :)
She is a mess.. haha
LOL...she IS a mess...and narcoleptic! I swear she sleeps more than any other dog I've ever had!


text:
1 Review
5 star
3 star
2 star
1 star
Average Customer Review
Share your thoughts with other customersCreate your own review
Most Helpful First | Newest First
4.0 out of 5 stars The Toronto Blues Jays repeat as World Series champions,
Lawrance Bernabo (The Zenith City, Duluth, Minnesota) - See all my reviews
This review is from: 1993 World Series (VHS Tape)
The David and Goliath roles in the 1993 World Series were obvious to everyone. The Toronto Blue Jays were the defending World Champions, back to become the first team since the 1978 New York Yankees to win two titles in a row. Meanwhile, the Philadelphia Phillies had finished last the previous year, so making the World Series was something of a surprise, led by young ace Curt Shilling, wildman reliever Mitch Williams, and sparked by Mets castoff Lenny "Nails" Dykstra, who hit four World Series home runs for Jim Fregosi's club. The series MVP was Paul Molitor, who batted .500 and had 8 runs batted in during the six games.
The signature moments of this series were Game 4, the longest game in World Series history at four hours and fourteen minutes, won by the Blue Jays 15-14, which also made it the highest-scoring game in postseason history. At the end of three innings it was 7-6 Toronto, with both starters gone, but by the end of seven Philadelphia was up 14-9. Then the Blue Jays shelled two Phillies relievers for 6 runs. Of course the next game was a pitching duel won 2-0 by Schilling to stave off the end for the Phillies. In Game 6 Joe Carter hit the Series-winning home run on a 2-2 pitch off of the Williams with two outs in the bottom of the ninth, the first championship walk-off homer since Bill Mazeroski for the Pirates in 1960.
Blue Jays fans will want both the 1992 and 1993 World Series videos, and they will see that the common denominator is their team's two championships is scoring runs late in the game. Unfortunately the 1994 World Series was never played, so Cito Gaston's team never had the chance to go for the three-peat. For Phillies fans, losing a World Series they were never supposed to be in is certainly worth remembering.
Most Helpful First | Newest First
1993 World Series (VHS Tape - 1993)
Used & New from: CDN$ 8.99

subset: commoncrawl


text:
Where To Find Essay Writing Services Review? Read Here!
More Info
|(9.33 / 10)
|Visit Site
|(9.08 / 10)
|Visit Site
|(9 / 10)
|Visit Site
|(8.92 / 10)
|Visit Site
|(8.25 / 10)
|Visit Site
Because of the increase of the needs of people in help with writing essays essay writing service scams has also increased. That is why this article provides essay writing services reviews so that you will understand which is the legitimate essay writing service and which is the essay writing service scam. There are many victims of scams online and we don't want that to be you. As much as possible we at EssayWritingsReviews.com will ensure that you will get the right and legitimate service online. That is why we are willing to explain to you that you can trust our services and we are proven to be legitimate.
Things that makes us a legit essay writing service:
- We have been providing services for years
- We have a record of more satisfied customers
- We are trusted by more people and other known institutions
- We promptly answer our clients with our 24 hour service
Possibly The Best Essay Writing Service Out There
It's hard to look for trusted essay writing service nowadays and it's also hard to know which essay writing service is the best. Well, the agony of searching is over because the EssayWritingsReviews.com is here! We offer not only quality paper every time, we also offer top of the line customer service. We make sure that our clients are satisfied and happy with our services and our productions. That is why we have more elite writers in the team who have good knowledge on any subject and personal relations training.
We Have Online Essay Forums
At EssayWritingsReviews.com we have essay writing service forum wherein our previous customers and present customers can discuss what they have experienced from our services. You are free to ask questions and present your concerns or suggestions to us and we are happy to answer you questions. Here, you can also discuss our services with us and other customers online. Here you will read live responses from people and interactions.
We Have Custom Essay Writing Service Reviews
Apart from online forums we also have essay writing reviews wherein our customers can give their testimonials and honest evaluation of our services. On our essay writing service review pages you will find honest and true remarks of our clients with regards to what they have experienced from us. We are confident that we have given our clients total satisfaction. So you can read and see that we are the best writing service online. Our custom essay writing services reviews can be found in our website at EssayWritingsReviews.com.
Services We Offer
We offer different writing services such as: writing your essay, thesis, term papers, personal statement, application letter, articles, book review, assignments, homework, lab reports and more. We at EssayWritingsReviews.com offer our best service at a very low price.
Our services are proven for many years and we have lots of experiences in different types of writing materials. That is why we pride our services as top of the line among other writing services online. We offer only that best that is why we have the best group of award winning writers that display unmatched versatility and speed. So visit us now and buy our products. Our website is available 24/7 to take good care of your needs. Just send us the details and we will have it done in no time!


text:
Tech Info
- Nominal Voltage: 24
- Wattage: 10
- Amps: 0.40
- Bulb Dia.: 3/8"
- Bulb Length: 1-1/8"
- Package Size: 2
This product ships in 1 business day.
Add to Cart and enter your Postal Code to determine the shipping charges and estimated delivery date.
* Most products and orders leave our warehouse in 1 business day. However, select items may take more processing time. Alaska and Hawaii orders please add 1 additional warehouse processing day.
Standard Shipping Policies


text:
Blame Second in World Thoroughbred Rankings
Blame 's performance in the Breeders' Cup Classic is the best performance on a non Turf surface in 2010 according to the World Thoroughbred Rankings, and places him second overall behind English-bred Harbinger, who continues to lead the way on the strength of his outstanding 11-length triumph in the King George VI and Queen Elizabeth Stakes sponsored by Betfair (Eng-I) at Ascot in July.
Zenyatta so nearly made it 20 wins from 20 career starts, gaining relentless ground from the tail of the field to go down by a head. The winner of 13 grade I races, Zenyatta is the top filly or mare both on dirt and on artificial surfaces, but she has now been joined as one of the leading female racehorses in the world by Goldikova, who became the first horse to win three Breeders' Cup races when taking the TVG Breeders' Cup Mile (gr. IT) for the third successive year in impressive style.
So You Think became the highest rated Australian-trained horse since the inception of the World Rankings in 2004 with his victories in the Caulfield Yalumba Stakes (Aust-I) at Caulfield, the Tatts Cox Plate (Aust-I) at Moonee Valley and the Longines Mackinnon Stakes (Aust-I) at Flemington.
However, So You Think's winning streak came to an end in the Emirates Melbourne Cup (G1), in which he finished third to French-trained Americain, who recorded the best performance by a stayer so far this year with his 2.75L success.
Also in Australia, Black Caviar recorded her eighth win in as many starts with a dazzling display to take the Patinack Farm Classic (Aust-I) at Flemington by a commanding four lengths. In the process, she joined Sacred Kingdom at the top of the sprinting tree, and became the third highest rated female in the current World Rankings behind only Goldikova and Zenyatta.
In Japan, Buena Vista also stamped herself a world-class filly when running out a very decisive two-length winner of the Tenno Sho (Jpn-I) in Tokyo from Pelusa, who is now the highest rated 3-year-old in Japan.
English-bred Twice Over completed a notable double when taking the Emirates Champion Stakes (Eng-I) at Newmarket for the second successive year, defeating French-bred Vision D'Etat and Irish-bred Arlington Million (gr. IT) winner Debussy.
The World Thoroughbred Rankings are compiled by the World Rankings Supervisory Committee and published by the International Federation of Horseracing Authorities.
Copyright © 2015 The Blood-Horse, Inc. All Rights Reserved.


text:
404 File Not Found
Host by NetBox Version 2.8 Build 4128
Red Dingo Reflective Dog Lead
Keep your dog safe and looking his best with this Red Dingo Reflective Lead. This leash features a reflective bones pattern, and is designed for both comfort and control. It is made with premium nylon webbing, and features interchangeable leash clips.
The Red Dingo Reflective Leash is available in mid-blue, red and black. Small, medium and large sizes are available.
|.5 inch x 6 foot
|.75 inch x 6 foot
|1 inch x 6 foot
Please choose which cart you want to add the item.
By choosing one of the above, you are able to shop for both yourself and a registrant at the same time. Once you are ready to checkout your items will be waiting for you in both your personal and registry shopping carts.
Still need assistance?
Please contact us at 1-866-SHOP-WAG (1-866-746-7924)


text:
Forget getting DVDs in the post, now you can streams flicks on your PS3 with Lovefilm.
Last month's news that LoveFilm was finally making its way to the PS3 had us all het up here at T3 Towers. And now, at last, the app which lets you stream from a library of 2,000 movies is finally up for grabs.
Punters who stump up for the current £5.99 a month package can get involved, as can those who pay a higher monthly fee. If you have a £9.99 bundle you can stream as many films as you like, but if you pay £5.99 you're limited in the number of movies you can watch on your PS3.
If you use the PS3 service, it doesn't affect your standard LoveFilm deal and you still get DVDs, Blu-rays and games in the post as normal.
And fear not, LoveFilm says that even if your broadband is as sluggish as 2Mbps, the service should work fine. The app is appearing now on your XMB, so fire up the PS3 and take a peek at what's on offer. And don't forget to tell us what you think of it on our Facebook and Twitter pages.
Via TechRadar


text:
This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy.
Main content | back to top
Reporting in line with the Global Reporting Initiative
We use the Global Reporting Initiative's G3.1 guidelines for the Shell Sustainability Report 2013, our 2013 Annual Report and Form 20-F, and this website. GRI confirm that we have applied the G3.1 guidelines to an A+ level.
What is the Global Reporting Initiative?
The Global Reporting Initiative (GRI) has developed Sustainability Reporting Guidelines that strive to increase the transparency and accountability of economic, environmental, and social performance. The GRI was established in 1997 in partnership with the United Nations' Environment Programme. It is an international, multi-stakeholder and independent institution whose mission is to develop and disseminate globally applicable Sustainability Reporting Guidelines. These guidelines are for voluntary use by organisations for reporting on the economic, environmental, and social dimensions of their activities, products and services. The Global Reporting Initiative released its G3 guidelines in 2006.
We recognise the value of the GRI in assisting the process of improving disclosure by identifying better sustainability indicators, and in enhancing the comparability and standardisation of reporting. In 1999 we began to work with the GRI to test their guidelines and support their further development. We continue to use the G3 guidelines for our sustainability reporting. We use the G3.1 guidelines for our sustainability reporting that includes the Oil and Gas Sector Supplement.
GRI confirm us as A+ reporters
GRI confirm us as A+ reporters: see the statement GRI application level check
See the complete GRI Content Index 2014 for Shell.


text:
Share a Valentine's Day moment!
So this giveaway hop will be a little different than it usually is! To celebrate the most romantic event of the year, we'll have a GRAND PRIZE created with donations!
I'd like to invite YOU to join us and help sponsor this giveaway hop by donating a prize. Giftcards are a great prize for our international followers, romance books, ebooks, swag or another items a romance fan may enjoy! Anyone who makes a donation will be credited as a Co-Sponsor on the this page (when the giveaway goes live) along with your site link. All Participating Blogs will post the grand prize along with their own prize info.
Click here to sign up or read more about this giveaway hop!


text:
|Periodicals A-Z | PUBLISHER's Journal Indexes
|Internet Resources
|Number in brackets is the linkrank. The lower the number the more popular.
|Cyndi's List [679]
Popular site for genealogy researchers
|Health & Safety Information on Household Products [217]
|Scambusters [738]
|Yahoo Finance [635]
Yahoo financial news and stock quotes
Updated: April 2, 2014


text:
March 8, 2014
Sophomore righty Kyle Funkhouser pitched six quality innings on Saturday to earn his second win of the season.
LOUISVILLE, Ky. - With senior catcher Shane Crain and junior infielder Grant Kay leading the offense, the 10th-ranked Louisville baseball team rolled to a 10-1 win over Miami (Ohio) on Saturday afternoon at Jim Patterson Stadium.
Crain (Lexington, Ky.) was 2-for-4 with a double, two RBI and a run scored, while Kay (Omaha, Neb.) was 2-for-4 with a double, three RBI and a run as the Cardinals (9-4) scored in five consecutive innings from the second to the sixth to gain command. Freshman designated hitter Will Smith (Louisville, Ky.) chipped in going 2-for-3 with a double, one RBI and scored once, while junior shortstop Sutton Whiting homered and scored three times in the win.
"I'm seeing the ball well right now after struggling a little bit last week," said Kay. "Yesterday was a disappointing loss and a tough one to take, but today, we got good pitching and got the offense going a little bit. Tomorrow, we have to get after it again and win this series."
On the mound, sophomore righthander Kyle Funkhouser (Oak Forest, Ill.) allowed only one run on four hits with four strikeouts in six innings to earn the victory and improve to 2-1 on the season. Lowering his season ERA to 2.84, Funkhouser won his seventh career collegiate game while making his 10th career start.
"It wasn't one of my best days but I battled and got out of some jams," Funkhouser said. "I struggled locating throughout the game but I was able to make a couple of quality pitches when I needed to. We also had some timely plays defensively that got us through it."
Following Funkhouser on the mound was freshman lefty Robert Strader (Louisville, Ky.), who worked two innings of shutout relief, while freshman righty Ryan Lauria (Roanoke, Va.) recorded the final three outs of the game with a scoreless ninth inning.
Having split the first two games of the weekend series, the Cardinals and RedHawks will play the deciding third game on Sunday at 1 p.m., ET at Jim Patterson Stadium and admission is free.
The Cardinals struck first on Saturday when Crain delivered a two-run double down the left field line against Miami starter Nathan Williams to score freshman second baseman Nick Solak (Woodridge, Ill.) and junior outfielder Mike White (East Orange, N.J.) in the second inning. It was the second double of the season for Crain, who now has six RBI this season.
Miami (4-7) cut the Louisville lead to 2-1 in the top of the third with a RBI groundball off the bat of outfielder Matt Honchel. The RedHawks threatened for more in the inning but a 7-2 double-play on a perfect throw from senior Jeff Gardner (Louisville, Ky.) in left field to Crain behind the plate cut down shortstop Chad Sedio for the third out of the frame.
The Cardinals then pushed the advantage back to two at 3-1 in the bottom of the third when Kay scored from third on a RBI sacrifice fly to deep right field by Smith. Kay started the inning with a double off the base of the wall in left center before moving to third on a groundout.
An inning later, Kay delivered his first RBI of the afternoon with a two-run single up the middle to score Crain and Whiting. Crain had singled earlier in the frame while Whiting reached on a two-out fielding error at first by John Crummy to extend the inning. After a two-out walk to senior outfielder Cole Sturgeon (Owensboro, Ky.) loaded the bases, Kay blistered the first offering of the at-bat from Williams into center to extend the lead to 5-1.
White added another run to the advantage in the fifth with a RBI sacrifice fly to center to score Smith, who doubled to lead off the inning. The Cardinals tacked on three more runs in the sixth, including two unearned thanks to a throwing error on Miami. Kay plated the final run of the frame with a RBI groundout.
After a scoreless seventh inning, Louisville pushed across the final run of the afternoon in the eighth inning when Whiting sent a 1-0 offering from Miami reliever Ryan Haynes over the wall in right field for his first home run of the season. The solo shot was the second career home run for Whiting.
Williams suffered his second loss of the season for the RedHawks after allowing eight runs, including five earned, on seven hits with four strikeouts and four walks in five innings. Offensively, no Miami player had more than one hit in Saturday's loss.
Fans can follow Louisville baseball on Twitter (@UofLBaseball) at http://twitter.com/uoflbaseball and on Facebook at http://www.facebook.com/ulbaseball.
Louisville Postgame Notes
- After going nearly four full seasons without turning four double plays in a single game, Louisville has converted four in each of the first two games of the series with Miami.
- The stretch of five consecutive innings with a run scored on Saturday is the second longest streak of the season for the Cardinals trailing only the eight straight innings with a run across two games on Feb. 21-22 against Western Michigan.
- Saturday marked the eighth time this season Louisville has allowed two or fewer earned runs in a game.
- The Cardinals improved to 7-0 this season when out-hitting the opponent and 5-0 against righty starters.
- Junior Grant Kay earned his first career collegiate start at first base on Saturday after previously starting at second base (eight starts), third base (one) and designated hitter (three).
- Freshman Nick Solak made his first ever start at second base on Saturday after four previous starts as the designated hitter.
- Senior Cole Sturgeon earned his first triple of the season on Saturday and his eighth career three-bagger.
- Sturgeon has hit safely in nine straight games and has reached base safely in 13 straight.


text:
Metal Gear Scanlon 4 - Part 05
Become Premium to Watch
This re-release seems unnecessary at first glance, but the conclusion of Kratos' journey serves up a level of spectacle that remains impressive in 2015.
Her Story is a bold and largely successful experiment in interactive crime fiction.
Rocksteady's gorgeous-looking third Arkham game refines its open-world format a bit and lets you drive a whole hell of a lot of Batmobile.
Object »
The AH-64 is an Attack Helicopter specializing in the destruction of enemy vehicles and infantry. It appears in a number of games.
An emergency helicopter in the GTA series.
The Annihilator is a military helicopter found in GTA 4.
A fire fighting helicopter in the GTA series.
A Terran air unit. Has the ability to turn invisible.
A transport helicopter used in the Vietnam war.
A small attack helicopter in The Ballad of Gay Tony.
The Care Package is a killstreak reward in the Call of Duty franchise.
A large helicopter in the GTA series.
Fluffy looking puffs seen in the atmosphere that are accumilations of moisture. They are used to add detail to Sky boxes in games or just increase realism.
A flying warship of the Empire and a stage from Gunstar Heroes. Players must board the ship as it takes off and defeat Orange to retrieve a mystical gem.
Girders are the life blood of most modern architecture. They can be jumped on, climbed up, thrown, or bent by some kind of bending robot.
A small helicopter in the Saints Row series.
A helicopter in Saints Row 2.
The flying vehicle from the Halo franchise that can hold up to three people.
The Hunter is a military helicopter found in the GTA series.
A heavy Combine attack helicopter based from the Half-Life series. Quickly pursues and attacks targets typically in urban areas.
The workhorse of the Coalition of Ordered Governments.
A helicopter found in the GTA series.
A mini gyrocopter in the GTA series. It has working machine guns that fire Uzi bullets when used.
The Maverick is a helicopter found in the GTA series.
This fearsome Russian attack helicopter has featured in many games, an annoyance in flight sims and action games your best tactic would be to shoot them down fast.
A Russian anti-armor attack helicopter.
The News Chopper is a variant of the Maverick from the GTA series. It is also called News Maverick or VCN Maverick, depending one what game you are playing.
Large VTOL craft used to move troops and cargo
Last resort when falling from the sky. Allows the user to glide to safety with ease.
The Police Maverick is a law enforcement helicopter found in the GTA series.
A Helicopter in the GTA series.
A small remote controlled helicopter in the GTA series. It has a magnet under it for picking up objects and dropping them.
This edit will also create new pages on Giant Bomb for:
Until you earn 1000 points all your submissions need to be vetted by other
Giant Bomb users. This process takes no more than a few hours and we'll
send you an email once approved.
Because you're new to wiki editing, we sent your
submission off to our moderators to check it over. Most
changes are approved within a few hours. We'll send an
email when it is.
Once you've earned over points you'll be able
to bypass this step and make live edits to our system.
Until then, gain points by continuing to edit pages.
No changes were submitted, nothing was done! Please make changes to the wiki!
Thanks for continuing to improve the site. Some of your changes are
now live. However, some of your changes were sent to moderation because you do not
have enough points to make those live edits. You need points to
live edit the changes you commited.
For the changes that went through, our robot math gave you points for this
Thanks for continuing to improve the site. Your changes are
now live. Our robot math gave you points for this
Use your keyboard!
Log in to comment


text:
I talked about this subject Wednesday on the "Martin Bashir Show" and on "The Last Word" last night. But it bears repeating: the Republican Party's political operatives, and its media hacks (think Rush, Hannity, Coulter…) have been rolling the conservative base for decades, pretending to cleave to their values, but hiding them in the back room when it's time to talk (or implement) policy. Well, the base isn't having it anymore.
Here's a clip from this week's column:
For decades, Republican political operatives like Karl Rove have used the right — both Christian conservatives and Ayn Randian Libertarians — to win elections. Once in power, however, Republicans have been loath to govern on conservative principles, believing — with some merit — that the actual policies would be widely unpopular.
Instead, GOP politicos have tried to force the right into the cuddly branding of "compassionate conservatism" or the "ownership society," rather than presenting the ideology as it is — and selling it the way the right imagines Ronald Reagan did. That's the main conservative critique of the Bush years. (The trouble with the myth, of course, is that Reagan never lifted a finger to ban abortion, plus he raised taxes, exploded the deficit and granted amnesty to illegal immigrants, none of which has interrupted his deification by conservatives.)
Eight years later, the far right need no longer worry that its ideology is being hidden under a bushel, or wasted on politicians too timid to act.
The 2010 elections brought to power conservative governors and state legislatures, not to mention the tea party-heavy 112th Congress, particularly the U.S. House of Representatives, who together have floated literally hundreds of abortion-related bills, pushed for "personhood" amendments that would ban the IUD and fought for religion-based restrictions on the distribution of birth control through employer-provided insurance plans.
It's ironic that Christian conservatives are returning to political prominence at the same time as laissez-faire, 1-percenter-worshipping Ayn Rand Libertarians — Rand herself was an unabashed atheist, who was contemptuous of the "mysticism" of religious people.
Contradiction aside, that duality is at the heart of Republican politics today — witness Paul Ryan, the GOP vice presidential candidate who is at once a religious fundamentalist on the question of abortion, and a Randian when it comes to, say, Medicare privatization, tax cuts for the rich and slashing spending on programs for the poor. …
… Movement conservatives, whether they are of the Koch brothers — "end the minimum wage and child labor laws, and cease all regulation on big business and the extractive industries" strain — or the evangelicals who even now are writing into the platform for next week's Republican convention a plank opposing abortion rights for women, even in the case of rape or incest, are finally having their day.
Not that the political and media hacks get that they can't just roll over the base anymnore, nor can they shut them up. Don't believe me? Here are a few headlines for you to ponder…
This New Hampshire Republican sheriff's candidate says he would use "deadly force" if necessary, to prevent an abortion from taking place.
And these Christian conservatives are not amused by the party operati abandoning Todd Akin. Not amused one little bit. The term they've used to describe their lack of amusement? "Political gang rape." Seriously.
This Christian conservative leader agrees: Todd Akin is the one being "forcibly assaulted" here. Really.
And Akin is fundraising off his … er … gaffe (which wasn't really a gaffe because he still believes it…)
Oh, and of course, there's this guy.
Read more here.
And here are my Bashir appearance today on the subject:
Visit NBCNews.com for breaking news, world news, and news about the economy
… and myself, Richard Wolffe and Newsweek's Michelle Goldberg on "The Last Word" discussing the present state of GOP hackduggery when it comes to their evangelicals:
Visit NBCNews.com for breaking news, world news, and news about the economy
And here's our "Very Last Word":
Visit NBCNews.com for breaking news, world news, and news about the economy


text:
Yourhouse Guesthouse Reviews
- Info
- |
- Rates
- |
- Map & Directions
- |
- Reviews
- |
- Facilities
Reviews & Ratings Explained
The rating percentage is calculated from customers who booked within the last 12 months.
All ratings and reviews are based on the feedback and opinions of the customers who submitted them and do not express the opinions of Hostelworld.com. This way, you get an up-to-the-minute opinion of just how good a hostel really is.
Read our review guidelines »
We stayed in YH#2. Double room with en suite and fan. Excellent value at 300B /nt. Clean, bed reasonablely comfortable, HOT water. Great position in old town. Walk to everywhere. Didn't eat here -we are street food fans :) Not a hostel set up to introduce people, more a budget motel.
- Novice Nomad
- helen1541
- Australia
- Couple, 41+
- (2 reviews)


text: Temple View Rv is proud to unveil its new Blog. We feel that this is a better way to keep you, our loyal customers up to date with not only the RV park but the goings on all around us. We hope that you enjoy reading our posts and that you bookmark us and stop by regularly.


text:
|Product #: TCR3385_TQ
Nonfiction Reading Comprehension Grade 5 (Resource Book Only) eBookGrade 5
Ships Free!
Please Note: This ebook is a digital download, NOT a physical product. After purchase, you will be provided a one time link to download ebooks to your computer. Orders paid by PayPal require up to 8 business hours to verify payment and release electronic media. For immediate downloads, payment with credit card is required.
After reading brief nonfiction passages about science, geography, or history topics, students answer multiple-choice and short-answer questions to build seven essential comprehension skills.
The activities target standards in these areas:
- main idea
- drawing conclusions/ making inferences
- stating opinion and supporting it in writing
Customer Reviews:
Submit a review


text:
Dodgers beat Pirates 4-1
WP: Chad Billingsley (1-0)
LP: Erik Bedard (0-2)
S: Javy Guerra (4)
Some thoughts on the game after the jump...
- The lack of hitting by this team scares me. If it wasn't for the pitching, we could still be looking for our first win.
- Clint Barmes got his first hit of the season, a solo home run that gave the Bucs the lead in the 3rd.
- Neil Walker is 1-17 (.059) at the plate this season. Last year after 5 games, he was 7-21 (.333).
- It was nice seeing Nate McLouth start again in a Pirates uniform. Wouldn't that be nice if he regained his All-Star form.
- Dodgers' 5-1 record so far is the best start they've had since 1999.
- Matt Kemp's streak of RBI in consecutive games was snapped at nine.
- Clayton Kershaw was presented with his Cy Young Award on the field before the game. Hopefully we'll see Gerrit Cole or Jameson Tallion posing with this award in the future.
Three Stars
3) Matt Guerrier (Scoreless top of 7th)/ Clint Barmes (1-3, HR)
2) Chad Billingsley (6.0 IP, 5 H, 1 ER, 4 K)
1) Juan Rivera (3-4, 2 RBI)


text:
Padded protection for the 104HR.
Keep your Markbass 104HR bass cabinet protected with this cover made from polyester, foam, and nylon.
Item # 107220873 | Condition: Info | Customer Ratings: ( 5 Based on 3 reviews)
Condtion Rating
Usually arrives in 3-5 Days
3 on hand
Apply to all available items
This location is not authorized to sell products.
Please select an authorized location.
Protect Your Gear
Accidental damage, normalNormal wear and power surges are no longer an issue with these comprehensive and affordable plans. We even pay to ship your gear for repairs. More details.
Covers much more than the original manufacturer's warranty:
Limit of Liability: The least of the cost of (1) authorized repairs, (2) replacement with a product of similar features, (3) reimbursement for authorized repairs or replacement or (4) the price that you paid for the product.
*Limitations and exclusions apply. See terms and conditions for program details
Keep your Markbass 104HR bass cabinet protected with this cover made from polyester, foam, and nylon.
Very nice quality - even has a light layer of padding for when I'm banging it into stuff or hauling in the rain. Fits perfectly over my 104HR. A must have if you're spending the money on the cab.
Like everything that Markbass produces, the Standard 104HR Bass Cabinet Cover is top quality. The material and padding is surprisingly thick. I can't imagine not having this protective cover. Smart investment!
Nice Cover! I like everything about Markbass.
For your convenience, our online inventory has been expanded to include items in our retail locations. Some items may be fulfilled from Guitar Center retail stores*. Items will be inspected to ensure the store has the product you want, in the condition you expect. If not, a store manager will contact you by phone or email within one hour.
*Select items are available for in store pick-up only
Your message has been sent.
PO Box 4769
Westlake Village, CA 91359
|* Denotes Required Field
|Order #:
|(if applicable) * Denotes Required Field
|*First Name:
|*Last Name:
|Contact Preference:
|Best Time to Contact:
|Click to add file attachment
Sending Message...


text:
Hold down Control (PC) or Command (Mac) key + mouseclick to select more than one option
|Avg. Dinner Entrée
|Greater than $25
|$18.01 - $25
|$12.01 - $18
|$7.01 - $12
|Less than $7
Posted by IHeartfood on 12/04/2013
Everything was perfect...food and service was unbelievable and probably one of the best French place i ever been to! Nothing fancy smancy about the decor...just a good place to eat and waiters are extremely friendly!
Posted by jordan on 02/07/2013
Visited for the first and last time in January. Let's start with the wooden tables -- no tablecloths though the photos indicated them and the hardest chairs I've ever endured. Rough around the edges to say the least, for a "modernist" French bistro. Two men at a neighboring table were fervent regulars and suggested the mussels. They would surely have been a vast improvement over the dull atlantic salmon pave "en papillotte." Steamed fish and vegetables were completely flavorless. So if you go, you might be safer with the mussels. To be fair, there were not many dishes sampled, but the two entrees were unremarkable.
Posted by DiningDeacon on 08/06/2012
Thank you for opening in my neighborhood. I have eaten here several times and have sampled at least half the menu. Everything I've had was at least very good, and often excellent (except for one over-fried "special" crabcake.) Standouts are the crab-and-avocado napoleon, sweetbread tarte, squab, short ribs, and fish. Three courses, lovingly plated, for only $40. Why can't other places do that? The service is pleasant, and there are good, affordable wines by the glass. The only mystery is that Old Masters painting on the wall, but we can live with that.
Posted by Greg on 04/22/2012
What a welcome addition to 14th St. This place is special. It replaced a French bistro, Gravoche, which was a neighborhood favorite. They opened in the space and kept a similar type menu and vibe. Plus they have a fantastic garden in the back! The food is remarkable and priced just right. The staff is very friendly and the noise level is comfortable. This is a great restaurant with a great staff and excellent food. Their soufflé's are worth a visit. Do yourself a favor and try Jeanne & Gaston. You won't be sorry!
Posted by Mia on 03/20/2012
My husband and I have had several memorable dinners here and are always happy to introduce friends to enjoy this lovely restaurant. It is comfortable chic and offers wonderful food served by attentive, personable waitstaff. The added bonus is the fact that we can choose any (!) appetizer, entree and dessert on the menu for $40. We have already found favorites such as the French pizza appetizer (not sure of the name) and scrumptious dessert souffles but we want to try more because everything is just so tasty. Today, we're bringing a British friend there for lunch...can't wait!
Posted by Anonymous on 02/13/2012
We have had two dinners at Jeanne & Gaston, both excellent. The three-course $40 prix fixe is a good buy. The restaurant has been redecorated and is very pleasant. The noise level, even when the restaurant is full, is acceptable. Wine prices are reasonable. Food portions are generous without being gross, and the quality is high -- everything we've had is delicious. Only the service needs improvement to be truly professional -- especially the helpful busboy who called us "you guys" each time he came over to the table. That didn't add to the French atmosphere.


text:
So I go into a Cozymels mexican restaurant in Grapevine and there is a notice saying no guns permitted without a license. Gotta love it.
I'd move here if it weren't 80 degrees this time of year before friggen sunrise!
Tell me about it, I live in Grapevine. I love Cozymel's.
Forum Rules


text:
Club captain John O'Shea has served a one-match ban while recent arrival Emanuele Giaccherini is back after missing the home game with Arsenal through injury.
O'Shea's suspension allowed him to shake off the injury he picked up playing for the Republic of Ireland in the recent World Cup qualifier against Austria.
Speaking to the club's official website, former Swindon boss Di Canio said: "They are ready to be selected.
"We know Giaccherini is crucial, and O'Shea, who is our captain, is a crucial player.
"There is no doubt that they will be in the game."


text:
Latest News
Sign-Up to Receive All City Council Prelights and Highlights
Reno Police Department Newsroom
Reno Fire Department Newsroom
Check out our Blog!
Media Contacts:
Matthew Brown, Communications Program Manager
Matthew oversees the City's press communications and public relations activities.
Deanna Gescheider, Director of Communications and Community Engagement
Deanna directs the Department of Communications and Community Engagement, this includes overseeing and managing strategic direction for the City's: media relations, print and new communications, television production and web services.
American Idol Bus Tour rolls into downtown Reno
The American Idol Bus Tour is scheduled to visit Reno on Saturday, July 12, 2014. Auditions will be held from 9 a.m. to 5 p.m. at City Plaza (30 N. Virginia St.).
More information can be found here: http://www.americanidol.com/
Only persons 15 to 28 years old are eligible to audition. No children younger than 5 are allowed at the event.
Cheerleaders from the University of Nevada, Reno and Damonte Ranch High School will welcome the bus to City Plaza at approximately 8 a.m. Members of the community are encouraged to come out and support the participants.


text:
Texas Politics
All Texas politics all the time from the San Antonio Express-News and Houston Chronicle
Posts filtered on Tag
Kinky Friedman wants to run for governor again
Musician and humorist Richard "Kinky" Friedman today formed a committee to raise money for a Democratic run for governor next year. Friedman in 2006 ran as an independent, drawing 12 percent of the vote — slightly more than a half-million votes. Here's Friedman's announcement: "Kinky Friedman today announced the formation of "Texans for Kinky," a […] [Read More]
Dee Dee Myers: Why Women (KBH?) Should Rule the World
Republican U.S. Sen. Kay Bailey Hutchison gets a few mentions in former White House press secretary Dee Dee Myers' book, "Why Women Should Rule the World." Myers doesn't endorse Hutchison for governor, but she does make an interesting observation regarding the "mentioning game that goes on before a presidential campaign, where pundits like me talk […] [Read More]
At a rodeo? At his childhood school (again)? In the Bahamas?
How do you think Gov. Rick Perry should kick off his re-election campaign? He's soliciting ideas now. First 10 people who submit suggestions will get an autographed copy of his book on Boy Scout values. If your idea is chosen, you get to take part in the kickoff. Perry in 2002 kicked off his campaign […] [Read More]
Former bureau chief to work for Schieffer
We just received this news release from Democrat Tom Schieffer's gubernatorial campaign: "Tom Schieffer announced today that former veteran state Capitol reporter Clay Robison will be the Director of Communications for the Tom Schieffer for Governor Exploratory Committee. Schieffer, a former United States ambassador to Australia and Japan who was also President of the […] [Read More]
Hutchison says Perry not leading on unemployment fund
U.S. Sen. Kay Bailey Hutchison said Gov. Rick Perry is not showing leadership in finding ways to avoid an employer unemployment fund tax increase next January. [Read More]
Hutchison says Perry taking too much credit for economy
U.S. Senator Kay Bailey Hutchison today told the Texas Daily Newspaper Association that Gov. Rick Perry takes too much credit for the Texas economy being better than the national economy. Hutchison said the governor's economic development fund is a good thing, but she said the economy has outpaced the national economy "not because he's handing […] [Read More]
Schieffer on steroids, eminent domain and stimulus funds
Forth Worth lawyer Tom Schieffer, who announced today his intention to explore a run for the Democratic nomination for governor, answered questions from reporters during a Capitol press conference about his time spent as the Texas Rangers president during the 1990s. Schieffer addressed concerns about whether he was aware that former Ranger Jose Canseco had […] [Read More]
Bush ally explores run for governor as a Democrat
Fort Worth lawyer Tom Schieffer, a long-time close associate of former President George W. Bush, officially launched an exploration of running for governor in 2010 as a Democrat today. Schieffer told a Capitol news conference that Texas education is not preparing the state for a place in a global economy. "At the very time when […] [Read More]
Hutchison camp: "Senator Bailout" nickname "smacks of desperation"
The Nickname is back. AP photos Perry/Huchison Mark Miner, spokesman for both Gov. Rick Perry's elected office and campaign, called fellow Republican Kay Bailey Hutchison "Senator Bailout" again, this time in the The Dallas Morning News. The comment came in a story revealing that the governor's campaign is looking into Ray Hutchison, the senator's husband. […] [Read More]
New poll shows Hutchison drubbing Perry in GOP primary
A new public opinion poll indicates U.S. Sen. Kay Bailey Hutchison would soundly defeat Gov. Rick Perry if the 2010 Republican primary were held today. Hutchison leads Perry 56 percent to 31 percent in the survey by Public Policy Polling. For a copy of the release, click here. The survey found Hutchison is viewed favorably […] [Read More]
Show More


text:
Temptalia Asks You – How do you justify a beauty product's price?
How do you justify a beauty product's price? Are there certain prices you'll pay? Certain prices you won't?
I buy what inspires me, in a sense. If there's a beauty product that really excites me, I'll probably buy it. Sometimes if it's very pricey, I'll think on it and see if I still want it in a few days. If I do, then I'll buy it.
Discussion and debate are highly encouraged, and we expect community members to participate respectfully. When asking a question, please check the FAQ section (above) for information about purchasing, price, dupes, and the like. If you have general feedback or need technical support, please contact us.
Comments that include advertisements, self-promotion, insults, etc. may be in violation of our comment policy and subject to deletion. Please see our comment policy for more information.


text:
Larissa Freedberg
No Photo
my teams purpose is to have all my questions answered and to hopefully be closer to knowing what i want to do with my life.
Career Exploration
Gregory Odle
Home Base:
Redlands East Valley High School
All Rights Reserved
i have multiple feeligs about this roadtrip. i am somewhat excited but im also very nervous. since i came to this school late this is the first lesson that i have actually been here for. i am trying (read more)
Written on April 22, 2010 at 12:00am
my roadtrip
this roadtrip was fun. i enjoyed it because i got to understand how somone just like me was able to find her road and that has helped me out a lot. its like my eyes were opened and now i have been (read more)
Written on June 3, 2010 at 12:00am
Start Date: 05/25/2010
Start Location: Redlands, CA
Total Interviews: 0
Miles Logged:
End Date: 05/25/2010
End Location: Redlands, CA
Total Views: 377
Inspiring (0)
Helpful (0)
Entertaining (0)


text:
Brian Nearing has a good story in today's Times Union about possible improvements at Grafton Lakes State Park. One of those improvements would include camping so you wouldn't have to leave the park once the sun goes down. There's also a plan for more trails and the Friends of Grafton Lakes have already been hard at work restoring the Dickinson Fire Tower. All great news for those of us in the Capital District.
If things work out, maybe you could spend the night
One Response
I'd love more trails at Grafton but I'd hate to see another beach. The north end of Long pond is pretty peaceful and I don't want to lose that.
I've walked up the trail and climbed to the fire tower a couple of times. I'm glad to see work being done on it.


text:
Blogging TV, one show at a time
Posts filtered on Category
Reaper: Fast cars and fast women
By Jonathan Harris If you've been hoping that Sam would be able to land it with a girl then you may or may not be pleased by this episode. This week's Reaper featured Sam's usual problems. The random vessel, an escaped soul from hell, and love troubles with Andi, but he finally made a connection […] [Read More]
Reaper: Doggone Halloween
By OLIVIA OPPENHEIM Sam, Sam, Sam, how do you always manage to always get yourself in some sort of predicament at work, (as both hell's bounty hunter and pumpkin flyer boy), and in your social life? Good thing you have your trusty best friends to help you whenever needed … right? So the episode begins […] [Read More]
Reaper: The sins of the father pass on to the son
By JONATHAN HARRIS Sam has gotten himself into another mess again and this time it's green, slimy and out for revenge, but we're used to that by now. In Reaper's last episode we found a Sam desperate to see the contract that has bound his soul to the Devil and in this installment the episode […] [Read More]
An apple a day keeps evil souls away
By Jonathan Harris Poor Sam, you would think that having powers given to you by the Devil would provide you at least some advantages right? Wrong. After Sam's bug problem last week he finds himself causing his valuables to disappear on this week's installment of the CW's Reaper. Sam wakes up as though it were […] [Read More]
College and cockroaches can't stop love
BY OLIVIA OPPENHIEM Sam must capture the soul of an angry mistress, Gloria, who sends insects to attack anyone who gets near her former lover, Harold Bunsen – all while juggling with his job at the Work Bench and a possible love triangle with Andi. Sam is given a vessel, the toaster, from the Devil […] [Read More]
Sam's got the power
Andrew Eccles : the CW Bret Harrison is Sam, the Devil's newest bounty hunter, on Reaper. By AUSTIN GROGIN When we last left the CW's devilishly fun Reaper, 21-year old underachiever and slave to the minimum wage Sam Oliver (Bret Harrison) discovered that his parents had sold his soul to the devil before his birth […] [Read More]
One hell of a good time
The CW Sam's in bed with the devil. By Austin Grogin Reaper, a one hour dramedy directed by the king of twisted humor Kevin Smith (Dogma), centers on the life of 21 year-old Sam (Bret Harrison from FOX's Grounded for Life and The Loop), a young slacker void of ambition just trying to gather enough […] [Read More]


text:
The Department of Defense announced today the death of a soldier who was supporting Operation Enduring Freedom.
Pfc. Cesar Cortez, 24, of Oceanside, Calif., died Feb. 11, in the Kingdom of Bahrain.
Cortez was assigned to 5th Battalion, 52nd Air Defense Artillery Regiment, 11th Air Defense Artillery Brigade, 32nd Army Air and Missile Defense Command, Fort Bliss, Texas.
For more information, the media may contact the 32nd Army Air and Missile Defense Command public affairs office at 915-568-3328.
CORRECTION: Feb. 13, 2011 -- The theater of operations is corrected from United States Mission Iraq to Operation Enduring Freedom.


text:
Brit Rock Film Tour 2014 - Trailer
© Posing Productions
© Posing Productions
"If you were wondering what Alastair Lee (aka Posing Productions) was up to following his 'big three' films with Leo Houlding, then look no further... it's the Brit Rock Film Tour!
But what is it? It's a collection of films including fell running and mountain biking, but more importantly it of course includes CLIMBING! Starring on the rock is Mina Leslie-Wujastyk in the film 'Project Mina' and Juian Lines in 'Stone Free'. Enough of my waffle, chack out the trailer below:
Video 2 mins 54 secs.
- Forums ( Read more | 1 comments, 27 Aug 2014 )
- This video has been watched 16,777,215 times


text:
Lockheed Martin is awarded a contract modification for C-130J large aircraft infrared countermeasures Group A kits and jump platform storage assemblies.
Northrop Grumman Systems Corp., Rolling Meadows, Ill., has been awarded a $6,637,223 modification (P00041) on contract (FA8625-12-C-6598) for large aircraft infra-red countermeasures (LAIRCM). The contract modification incorporates interim contract support of the U.S. LAIRCM line replacement units. The total cumulative face value of the contract is $529,124,094. Air Force Life Cycle Management Center/WLYK - LAIRCM, Wright-Patterson Air Force Base, Ohio, is the contracting activity.
Lockheed Martin Corp., Marietta, Ga., is being awarded a $7,340,724 contract modification for incorporation of Large Aircraft Infrared Countermeasures (LAIRCM) NexGen Sensors onto HC/MC-130J aircraft. The contracting activity is the Air Force Life Cycle Management Center, Wright-Patterson Air Force Base, Ohio.
Northrop Grumman Systems Corporation, Warner Robins Regional Support Center, Warner Robins, Georgia, is being awarded a $463 million requirements contract for sustainment of the AN/AAQ-24(V) Large Aircraft Infrared (LAIRCM) system. Work includes depot-level repair of 20 components of the AN/AAQ-24(V) LAIRCM system. Air Force Sustainment Center, Robins Air Force Base, Warner Robins, Georgia, is the contracting activity.
Northrop Grumman Corporation, McLean, Virginia, recently announced that it has been awarded a $334 million firm-fixed-price contract from the U.S. Air Force to provide Large Aircraft Infrared Countermeasure (LAIRCM) systems and support. The LAIRCM system functions by automatically detecting a missile launch, determining if it is a threat and activating a high-intensity laser-based countermeasure system to track and defeat the missile. Northrop Grumman will deliver LAIRCM hardware and provide associated support to the Air Force beginning immediately and continuing through April 2014.
Lockheed Martin Corporation, Marietta, Georgia, is being awarded a $7,967,982 firm-fixed-price contract for procurement of C-5 Large Aircraft Infrared Countermeasure System (LAIRCM) Group A hardware and assembly of the Group B (government-furnished parts) parts with the Group A hardware into nine C-5 LAIRCM kits; and initial spare parts. Aeronautical Systems Center, Wright-Patterson Air Force Base, Ohio, is the contracting activity.


text:
- Home
- DRF Bets
- Handicapping & PPsHorsemen's ProductsReports
Access past performances
- The Wizard
- DRF Gameplan
- Quick Sheets
- DRF Picks
- Today's Racing Digest
- Key Race Report
- Positive ROI Report
- Moss Pace Figure Reports
- Debut Reports
- BreezeFigs
- Clocker Reports
Racing and Wagering Information
- DRF EasyForm PPs
- DRF Classic PDF PPs
- DRF Formulator PPs
- DRF HarnessEye PPs
- DRF Daily Harness Program PPs
- Daily Racing Program PPs
- Equibase & Trackmaster PPs - Thoroughbred
- TrackMaster PPs - Harness
- Entries
- Results
- NewsCategoriesTrack Notes
- Blogs
- Learn
- Video
- StorePast Performances
DRF PlusREPORTSPICKS
- Compare all DRF PPs
- DRF Formulator PPs
- DRF Classic PPs
- DRF EasyForm PPs
- Daily Racing Program PPs
- Expanded Closer Looks
- Equibase & Trackmaster PPs - Thoroughbred
- Events
- Breeding
Keeneland January sale: Stonestreet strikes for Cosmo Girl at $190K
Stonestreet Farm continued to be active at the Keeneland January horses of all ages sale, with bloodstock agent John Moynihan signing the ticket on $190,000 Cosmo Girl to establish a new high price for a mare during Wednesday's third session.
The 6-year-old City Zip mare was offered as a racing or broodmare prospect by Baccari Bloodstock LLC. Chris Baccari, who raced Cosmo Girl, said he was pleased with the sale.
"I'm glad that Stonestreet bought her, because they'll breed her to nice horses," said Baccari, who purchased Cosmo Girl for $45,000 from the Sea Jay Farm consignment at the 2008 Keeneland September yearling sale. "It'll be good for her."
Cosmo Girl won four of 24 career starts for earnings of $156,237. She won the 2011 Carousel Stakes at Oaklawn, and was also stakes placed at Oaklawn and at Lone Star Park.
Cosmo Girl is out of the Personal Hope mare Ever Imelda, who is the dam of six winners from as many starters, including stakes winner Green Suede Shoes. Ever Imelda is a half-sister to Red Mischief, dam of Grade 1 winner Ermine.


text: Prev | Next Actress Blake Lively poses for photographers on the red carpet at the screening of Mr. Turner at the 67th international film festival, Cannes, southern France, Thursday, May 15, 2014. (AP Photo/Virginia Mayo, Pool) Gallery: Scenes from Cannes May. 16, 2014 @ 01:17 PM Stars hit the French Riveria to unveil their new work at the Cannes Film Festival this week in Monte Carlo. (u'nobuy',)


text:
Restricted Party Screening API
Restricted Party Screening is a compliance web tool that consolidates international interdiction lists to ensure that customer transactions do not violate regional, unilateral, or multilateral regulations by dealing with denied, debarred, and/or restricted parties. Examples include known terrorists, terrorist funding organizations, or parties guilty of trade violations. The Restricted Party Screening API provides a RESTful interface for searching the database of restricted parties. Single search and multiple record search are supported. An API key is required and responses are XML formatted.
API Key
Followers (0)
Sorry, no followers found for this API.
Developers (0)
Sorry, no developers found for this API.
API Mashups (0)
Sorry, no mashups for this API.
Source Code
Sorry, no source code for this API.
Sorry, no resources found for this API.
Developers (0)
Comments (0)
Followers (0)
Sorry, no mashups for this API.


text:
Recruitment to the first two dose levels has completed with the combination of BKM120 and radiotherapy being well tolerated. The study is now recruiting patients to the third and final dose level.
The final datalock for 6MP Trial is scheduled for beginning of June. The clinical paper will be written with the aim to send to the chosen Journal in September 2015.
SPARC trial is now open to recruitment at The Churchill Hospital, Oxford University Hospitals NHS Trust. This is a phase 1 study dose escalation study testing the use of Stereotactic Body Radiation Therapy (SBRT) delivered in the pre-operative setting for borderline resectable pancreatic cancers.
The primary objective is to determine the maximum tolerated dose (MTD) of margin-intensive SBRT delivered pre-operatively in the surgical management of pancreatic cancer.
Site set-up is progressing well at our other two study sites (Leeds Cancer Centre and The Beatson West of Scotland Cancer Centre, Glasgow). If you have any questions about the trial please contact the SPARC Trial team.
LINES & MEMOS opened to recruitment in the first non-UK centre in January 2015 & February 2015 respectively, at Istituti Ortopedici Rizzoli, Bologna, Italy
Principal Investigator: Dr Stefano Ferrari
An extension to the recruitment period has been granted, with recruitment now open until January 2016.
The expansion of the trial into Germany continues to go well, with 7 sites now activate and 7 patients recruited to date (22Apr2015).
After an approved substantial protocol amendment to the eligible patient population for the TARDOX Trial, the first patient has been registered this month.
On 24th March the initial launch meeting took place. Representatives from all Stage 1 sites attended in person or via teleconference. The SCALOP-2 team would like to thank all those who spoke and provided background on pancreas cancer, the trial rationale and radiotherapy quality assurance.
The recruitment period for the trial has been extended until February 2016.
An abstract based on the CHOP-OR Trial Primary Endpoint analysis has been submitted to the EHA 20th Congress of European Haematology Association conference, which will be taking place in June. We are hopeful to be offered either a poster or oral presentation session and will hear by the end of April 2015.
The CHOP-OR Protocol paper has been published by BMC Cancer - www.biomedcentral.com/1471-2407/15/52
The Primary Endpoint datalock has been performed this month. The analysis of the data has begun and an abstract for submission to ESMO European Cancer Congress 2015 is in preparation.
As part of study set-up a fantastic pre-trial SPARC Radiotherapy Workshop was held in Oxford on 27 February 2015. Thanks to all those from Leeds and Glasgow who made the trip down to Oxford and in particular to those that gave interesting and discussion stimulating presentations on neo-adjuvant treatment of pancreatic cancer, margin intensive radiotherapy and the radiotherapy quality assurance for the SPARC trial.
Thanks for the teams in Oxford, Leeds and Glasgow for submitting their test case pre-trial outlines and plans for our QA team.
Set-up packs have been sent out to Oxford, Leeds and Glasgow and we are really excited to say that we are on track for opening to recruitment late March 2015. If you have any questions about the trial please contact the SPARC Trial team.
The CTAAC application for trial extension has been successful and last patient last visit has been set for the end of February 2015.
CHOP-OR has closed to recruitment and is now in Follow-up phase. Thank you to everyone who helped us reach our recruitment target and we will keep everyone informed of the results when available.
The 6MP protocol paper has been published by BMC Cancer - www.biomedcentral.com/1471-2407/14/983
Anal cancer is often curable with chemoradiotherapy but in a small proportion of patients the cancer returns. These patients might benefit from a higher dose of radiotherapy to parts of their tumour than is given as standard. It is proposed that MRI or CT techniques may allow identification of tumours that are likely to relapse after standard treatment. The ART trial has opened and is comparing different types of MRI and CT scan to see whether one of these scans can identify tumours that relapse and pinpoint the area of the tumour involved. In the future, those tumours identified by the scan as likely to relapse could be targeted with a higher dose of radiotherapy. It is envisaged that this technique could be used to cure a higher number of cases whilst avoiding complicated long term side effects. More information about the trial aims and procedures can be found here.
Great news! SCOT is extending follow up period from the end of Nov 2014 to the end of Nov 2015. This will apply to all Stage II patients and to all Stage III patients who are yet to reach the three year time point in follow up, which will improve the power of the analysis of the primary end-point in the study, disease free survival (3yrs). An application to extend the study beyond Nov 2015 is submitted and an initial outcome is expected in Q1 2015.
6MP has now closed to recruitment and is now in follow-up. Thank you to everyone who help us reach our recruitment target and we will keep everyone informed of the results when available.
TARDOX is now open to recruitment. TARDOX is a proof of concept study to investigate the feasibility of targeted release of doxorubicin from lyso-thermosensitive liposomal (LTSL) doxorubicin (ThermoDox®) using ultrasound-guided focused ultrasound in patients with liver metastases from lung, breast or colorectal primary tumours.
We are please to welcome Essen Universitätsklinikum as our first site in Germany open to recruitment into the PACMEL Trial.
Since the randomised phase of the RADVAN trial opened in April 2013 recruitment has been more challenging than expected. this can mostly be attributed to the increased treatment options now available to this patient group since the trial was conceived.
The Trial Steering Committee has therefore agreed to close recruitment to the RADVAN trial as of the 30th April 2014.
We would like to thank everyone for their support of the trial.
An amendment to the protocol of this ovarian cancer trial was approved by the ethics committee in March 2014 to recruit additional patients to a 'tumour mapping' group of the trial. In addition to detailed analysis of tumour samples collected from patients before and after special treatment with paclitaxel chemotherapy (the 'single dose' group), this amendment will allow the researchers to collect and analyse tumour samples taken before and after standard chemotherapy and also collect data on these patients.
The final data lock for the trial was completed on 31 March 2014, we would like to thank everyone involved for the efforts in completing this enormous task.
We are proud to announce that the interim analysis of the trial has been completed and a favourable review has been giving by the DSMC (Data & Safety Monitoring Committee) and therefore will carry on recruiting.
The AspECT trial is submitting an application with CTAAC for an extension beyond the end of 2014. We will apply for an extension sufficient to keep the last patient recruited on follow up for 8 years, i.e. to the end of February 2017. The outcome of the application is expected this summer. In the meantime, the decision has been taken not to request reconsent for trial patients who have not yet been approached about extending follow up from 8 years to 10 years.
This study aims to determine the safety and tolerability of combining the experimental drug BKM120 and radiotherapy for the treatment of non small cell lung cancer. The study opened in April 2013 and the group of patients recruited to first BKM120 dose level completed at the end of December. The IMP was well tolerated at this dose level with no safety issues. The study is now recruiting patients to the next dose level. You can find more information on the trial aims and procedures here.
FOXFIRE continues to recruit well across the whole of the UK, averaging 9 patients per month. We have recruited 298 patients so far and we are on course to meet our revised target recruitment this year.
The final datalock for the trial is planned for 31st March 2014. We would like to thank everyone involved in this process for their support.
The DOC-MEK trial manuscript has been accepted for publication in Annals of Oncology and publication is expected later in 2014. The trial has two patients continuing on open label AZD6244 who are continuing to derive benefit from the treatment. Close-out of the other randomising hospital sites is going well and sites are requested to contact the DOC-MEK team if they have any questions regarding site closure.
The trial team in OCTO enjoyed meeting the site principal investigators and trial teams in London at the PACMEL away day on 10 Feb 2014 and we hope everyone who attended found the day helpful. PACMEL screening and recruitment is continuing well and recruitment is scheduled to close in December 2014. Site activations in the UK currently stand at 15 of 18 approved sites opened; negotiations are proceeding to activate up to 10 sites in Germany to recruit patients to the trial.
A reminder that the 6MP trial is actively recruiting and needs to reach a total of 65 patients. Currently 51 patients are registered (January 2014). Click here for more details of inclusion/exclusion criteria and participating sites:
Please also find a 6MP Sites Location Map here:
Christmas Office Hours & Emergency Contact Details
SCOT Recruitment closed 5pm on Friday 29th November 2013. the final recruitment total is 6144 patients - a fantastic outcome!
Thank you to all the sites and staff for their support.
Could we request that samples taken between 23rd December & 1st January are kept in the site fridges to be sent 2nd January 2014
1 Patients was recruited into the CHOP-OR Trial in September bringing the total number of patients to 33.
The SCOT trial is moving in to the final two months of recruitment, due to end recruitment at the end of November 2013. As of the 3rd Oct 2013 total trial recruitment is 5880 – thanks to sites for the excellent recruitment so far! Please keep up the good work to the end of recruitment period in order to maximise the power of the study - and the huge effort contributed by sites throughout the study duration.
2 Patients were recruited into the CHOP-OR Trial in August bringing the total number of patients to 32.
We are delighted to have received favourable ethical opinion for LINES, a euroSARC Trial of Linsitinib in advanced Ewing Sarcoma.
The translational aspect of the SCOT study, TransSCOT, with the aim to collect up to 5000 matched blood and tissue samples, was launched at the end of 2012. Tissue and blood collection packs have been sent to all UK sites; sample return has been very is good to date, at the start of Aug2013 1110 blood samples and 1035 pathology samples returned – approximately 27% of expected samples. Denmark is keen to contribute to transSCOT and processes to initiate collection are in progress. OCTO and Oxford Labs co-ordinate the blood sample collection, Glasgow CTU and the Glasgow bio-bank co-ordinate the collection of pathology samples. Recruitment progresses steadily - 5710 as of 01Sep2013. All sites are thanked for their support and encouraged to maintain the momentum to ensure recruitment target is reached.
A reminder that the 6MP trial is actively recruiting and needs to reach a total of 65 patients. Currently 44 patients are registered (August 2013). Click here for more details of inclusion/exclusion criteria and participating sites:
Please also find a 6MP Sites Location Map here:
The next AspECT datalock is on 28th August 2013 so please send in any completed CRFs to arrive at OCTO as soon as possible. All 4 year follow ups should have been completed by now.
3 Patients were recruited into the CHOP-OR Trial in July bringing the total number of patients to 30.
We have recently made a substantial and exciting change to the PACMEL trial in order to include a third drug for testing and a third randomisation arm. This will evaluate the efficacy and safety of paclitaxel with pazopanib, in addition to the established paclitaxel with GSK1120212 (trametinib) and paclitaxel alone arms. A non-randomised phase II trial of pazopanib with paclitaxel has shown promising results for the combination in this patient group, so comparison of pazopanib with the paclitaxel-only arm of the PACMEL trial is an important research question. Ethics and MHRA approval for the amendment has been received and implementation of the amendment at participating sites is ongoing. An additional 40 patients will be randomised to recruit the third arm and recruitment has been extended to December 2014.
6MP uses a Simon two-stage minimax design. In stage one, 30 patients were evaluated. If fewer than 3 out of the first 30 evaluable patients had shown a response after 8 weeks, the trial would have been stopped for futility. The Trial Management Group recently met to discuss the results from the first efficacy analysis, and concluded that the trial will continue to the next recruitment target of 65 patients, because more than 3 patients from stage one had shown a response to the trial intervention (the definition of response includes complete response, partial response and stable disease as measured by RECIST V1.1. This is CTAAC approved.)
ASCO ACCEPTANCE (31st May - 4th June 2013)
We are delighted that 6MP was accepted and presented a "trials in Progress" Poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. click here to see the poster.
There are two planned data locks this year, on 8th April and 28th August. When we do a data lock we freeze the data a point in time, and produce tabulations which we use to identify outliers, inconsistencies, and missing treatment or outcome data. We also look for things like missing final Follow Up CRFs for patients reported as deceased on an SAE or End of Treatment CRF . the DSMC expect their next annual report to show that ALL follow up and endoscopy data is complete for all patients up to and including the 4 year timepoint. Requests for outstanding trial data are sent every three months but please, in particular, try to catch up to the 5 year time point for all patients. To be included in the next data lock we need to have received your CRFs by 14th August 2013.
Current recruitment 2 Patients (June 2013)
The recruitment period has been extended to March 2014 to enable recruitment of 35 evaluable patients. Please continue to screen for eligible patients.
Another 2 patients were recruited in May 2013 taking the current total to 27.
The COG trial results have now been presented at both ESMO and the NCRI meeting and PRO results have been presented at the ASCO GI meeting. All presentations were very well received by the medical community and now a paper has been submitted to the New England Journal of Medicine. We will notify site staff once we hear if the paper has been accepted by the journal. 45 out of the 48 recruiting sites have been closed out and we are very grateful for all the hard work site staff have put into preparing COG documentation for archiving.
Regulatory approval was recently received for a substantial amendment to introduce intermittent dose schedules for the experimental drug AZD8931, in combination with XELOX . Patients are currently being screened and recruited to the new protocol for the dose escalation phase in order to establish the maximum tolerated dose of the combination.
We are pleased to report that the DOC-MEK trial results have been presented at ASCO (01 June 2013 - click here to see the poster) and the Society for Melanoma Research (11 Nov 2012). the publication has been prepared and submitted to peer-reviewed journal. OCTO have also submitted an abstract describing trial management of this Investigator-Sponsored NCRN-AstraZeneca alliance trial to NCRI in November 2013.
We are currently completing the analysis and writing up the results of the EnROL Trial. We hope to have a paper submitted during summer 2013. The results are also being presented at the following conferences:
We are preparing an application to CTAAC for funding for long term follow up of all patients. More details to follow in the summer.
Recruitment is being extended until June 2014. At the end of May 2013, we had recruited 209 patients and are over half way to our recruitment target of 320. to drive recruitment we are in the process of opening six more sites which include:
These Chemotherapy-only sites will feed into the two high performing radioembolisation sites at Leeds and Cambridge.
The dose escalation phase of the PACMEL Trial has now been completed and the randomisation phase has been opened to recruitment. We are currently in the process of opening 12 new sites for recruitment in to the randomisation phase, of which 6 have been opened (9 sites in total).
Recruitment to the safety cohort has recently been completed and we have moved to the randomised trial of whole brain radiotherapy with vandetanib or placebo. Five sites are currently active across th eUK and an additional five sites are currently being set up.
The translational aspect of the SCOT study, TransSCOT, with the aim to collect up to 5000 matched blood and tissue samples, was launched at the end of 2012. Tissue and blood collection packs have been sent to all UK sites and there has been an excellent return response from sites to date. OCTO and Oxford Labs co-ordinate the blood sample collection, Glasgow CTU and the Glasgow bio-bank co-ordinate the collection of pathology samples.
The BKM120 study has opened. This study aims to determine the safety and tolerability of combining the experimental drug BKM120 and radiotherapy for the treatment of non small cell lung cancer. BKM120 may act as a radiosensitiser by reducing tumour hypoxia (low levels of oxygen in the tumour) and the trial will examine the level of hypoxia in tumours before and after BKM120 treatment using imaging. You can find more information on the trial aims and procedures here.
Cancer Research UK Press Release 17 August 2012: Trial launch of urgently needed combination treatment for oesophago-gastric cancer
Data cleaning is in progress prior to our analysis data lock on the 20th August.
A welcome to Sweden who have joined the SCOT trial, the first site opened with 2 patients recruited.
We are very pleased to let you know that a late-breaking abstract for the COG trial has been accepted for presentation at the ESMO Conference in Vienna this September. As a means of reviewing the abstract prior to the conference and notifying sites of the initial findings of the trial, an Investigator Meeting is going to be held on Monday 17th September, and sites will be contacted regarding this in due course. During the meeting, Professor David Ferry and statistician Sue Dutton will present the abstract and listen to any feedback/comments that you might have. We look forward to sharing the results of this important trial with site staff who have worked so hard on it.
We are counting down the remaining CRFs to be submitted with our first post end of follow up data lock imminent on the 13th July.
We are delighted that the CHOP-OR trial remains on target with 15 patients now recruited.
Recruitment is going to be extended until 2014 and more information will follow via email.
6MP has recruited 25 patients. Our target is 48 patients by the end of July 2012. The trial is open to patients with known BRCA1 & 2 deficient locally advanced or metastatic breast cancer, advanced ovarian, fallopian tube or primary serous peritoneal cancer patients who have progressed after at least 1 previous line of chemotherapy. Analysis of the first 12 patients' safety data showed that the IMP is being well tolerated with no safety issues.
From Monday 18th June the AspECT trial lab will be open to accept blood and biopsy samples from all AspECT sites. The trial lab is now staffed by Neera Maroo and Barbara Zietek. If you need trial sample supplies, please email email@example.com or firstname.lastname@example.com
The lab address will remain the same (Blizard Institute).
The EnROL trial is now in the last month of patient follow up could all sites please ensure all data is submitted as soon as possible.
The EnROL trial management group has submitted and had accepted for publication a paper that described the design and methodology of the EnROL Trial. The paper will be published in BMC cancer.
Happy 1st Birthday to the CHOP-OR trial. The trial opened to recruitment on the 27th April 2011 so we are now into the 2nd year of recruitment.
Just 8 patients needed to reach recruitment target.
SCOT recruitment in Denmark is going well, 7 sites opened and 43 patients recruited since November 2011.
6MP has recruited 20 patients. We are aiming to recruit 33 patients by the end of April 2012. The trial is open to patients with known BRCA1 & 2 deficient locally advanced or metastatic breast cancer, advanced ovarian, fallopian tube or primary serous peritoneal cancer patients who have progressed after at least 1 previous line of chemotherapy.
The first 12 patients' safety analysis is underway and the results will be discussed by the trial committees at meetings in May. Many thanks for your valuable input to this important trial.
Aspirin for Cancer Prevention
Fresh evidence suggests that taking a low dose aspirin every day may prevent and possibily even treat cancer. The three new studies published by Peter Rothwell in The Lancet add to mounting evidence of the drug's anti-cancer effects. The AspECT Trial Management Group reviewed the latest evidence and immediately released a statement to all trial site staff.
If you are an AspECT patient and have any questions about this please contact the AspECT team at your recruiting hospital.
If you work on the AspECT trial at one of our sites please refer to the additional information here http://www.octo-oxford.org.uk/alltrials/infollowup/aspect/restricted.html
Professors Peter Rothwell and Janusz Jankowski were interviewed on this issue for the BBC Radio 4 programme 'Inside Health', presented by Dr Mark Porter, which was broadcast on 27th March 2012. You can download the programme here.
Professor Jankowski was also interviewed by Derek Bateman for BBC Radio Scotland's Newsweek programme. You can download the programme here.
Temporary ~ 3 month sample collection suspension for AspECT.
CHOP-OR CHOP-OR Trial has hit its first milestone 3 months ahead of target with the 10th patient being recruited in January 2012, just 9 months after the first site was opened to recruitment. We thank all participating sites especially Addenbrooke's and Royal Bournemouth who have both entered 4 patients each.
The SONATINA Team are pleased to report that all 8 patients have now been randomised into the Safety Cohort of the SONATINA trial. We would like to thank everyone involved with the recruitment of these patients onto the trial. Further recruitment to the trial is now on hold until the data from these patients is analysed in Spring 2012.
Protocol version 3 11Nov2011 and associated documents are now approved by MREC and MHRA. The amendment documents are available via CSP.
In October 2011, OCTO celebrated our 10th Anniversary! We've come along way since the office opened in 2001 with just three staff and a single trial. We currently have 9 actively recruiting trials, 3 in follow-up and more trials on the way in 2012.
Click on the link below to download a copy of our 10th Anniversary Newsletter which contains lots of information about OCTO and our trials.
COG recruitment phase is now closed having met the recruitment target. Final number recruited is 450 with 19 patients recruited during the first two weeks in November.
Protocol V5.0 has been approved by the main REC so the recruitment target for the trial is now 202.
We are pleased to announce that the Christie Hospital recruited their first patient into the EnROL trial.
We are pleased to announce that Denmark has become active in the trial with 1 site activated and 3 patients recruited.
In July 2011, NICE issued guidelines on the use of Radio-Embolisation in the treatment of liver metastases from colorectal cancer. NICE specifically named the FOXFIRE clinical trial as a "well-designed clinical trial" and used it as an example for others to follow in answering important research questions that may make a difference to the future treatment of patients with cancer. More information can be found at http://guidance.nice.org.uk/IPG401/DraftGuidance.
On the 1st October 2011 the EnROL trial entered into its final 6 months of recruitment. We are delighted that in October we hit our monthly recruitment target of 8 patients, just 40 patients left to go to hit our target.
Congratulations! With only 50 patients to go, we would like to extend our special thanks to our top recruiter sites:
We are pleased to announce that the EnROL trial has now recruited 152 patients with only 50 patients left to recruit.
We are pleased to announce that Spain has become active in the trial with 12 sites activated and 12 patients recruited during August.
CTAAC have approved our proposed reduction in sample size. An amended protocol will be submitted to ethics.
We are pleased to announce that the Christie Hospital recruited their first patient into the CHOP-OR trial.
SONATINA is study of nelfinavir addition to radiotherapy treatment in neo-adjuvant therapy for rectal cancer and is now open to recruitment at the Churchill Hospital.
6MP is a study of 6-mercaptopurine (6MP) and low-dose methotrexate in patients with BRCA defective breast or ovarian tumours and is now open for recruitment at the Churchill Hospital.
Congratulations! We are delighted to inform you that SCOT has now reached a significant milestone in our recruitment of 2000 patients.
A new study suggests that taking low doses of aspirin for at least five years can reduce the risk of dying from cancer. If people are considering taking aspirin on a regular basis, they need to weigh up the benefits and risks. The new study, published in the Lancet, was led by Professor Peter Rothwell. CRUK spoke to Professor Janusz Jankowski, the CI for the AspECT trial which is looking at whether aspirin can prevent oesophageal and bowel cancer. Here are his opinions and concerns about the latest findings.
Recruitment Update
COG is now over the half way mark, thank you for your ongoing support. Wishing everyone a very safe and joyful Xmas.
Oral bisphosphonates: oesophageal cancer risk—insufficient evidence of a link.
Recruitment Update
Recruitment Update
The last day to approach patients about QUASAR 2 will be 30th September 2010. You will then have until 17:00 (GMT) on October 15th to randomise them, after which time the database will lock and no further patients can be accepted. If you have any questions, please contact the QUASAR 2 team on 01865 617013.
Recruitment over the summer months for the SCOT trial has went very well. Thank you to everyone for your continued support and enthusiasm for the the SCOT trial! We are delighted to be fast approaching our 1,500th patient recruited. If each site recruits just 2 patients per month into SCOT we will reach our recruitment target of 9500 patients on schedule. Your contribution is invaluable. If you have any questions regarding the trial, please don't hesitate to contact us, we are always very happy to help.
Best Wishes,
The SCOT Team
We are pleased to announce that Charing Cross is now open to recruitment.
FOXFIRE Protocol V2.0 has been approved
We are pleased to announce that the EnROL Trial is now open to recruitment at Leighton Hospital
We are pleased to announce that Queen Alexandra Hospital, Portsmouth, is now open to recruit patients into the EnROL Trial.
QUASAR 2- Stage II patient randomisation closed.
PPIs and Clopidogrel - update
MHRA have recently updated their safety advice regarding the concomitant use of Esomeprazole and Clopidogrel. The published advice is available here: http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON076501
The MHRA advise that concomitant use of Clopidogrel and omeprazole or Esomeprazole is to be discouraged unless considered essential. AspECT Principal Investigators should carefully consider this information. Because it is not possible to completely exclude a possible interaction with Esomeprazole on the basis of available data, the potential risk of a slight reduction in efficacy of Clopidogrel should be weighed against the potential gastrointestinal benefit of the PPI. The TMG will consider possible further recommendations for AspECT patients at the next meeting to be held on 24Jun2010 and will provide further guidance after that date.
Recruitment Update - 12th April 2010
Just a quick message to clarify the situation regarding QUASAR 2 recruitment. Yes, we are still randomising stage II patients into the trial; the end of March 2010 was our (optimistic!) target for recruiting 1892 all-stage patients, but we still have 44 patients to go! Please do not feel that you can no longer consider these patients for QUASAR 2, and treat this as your last opportunity to offer this group of patients the trial.
You will be informed by the Trial Office when we have accrued 1892 patients and at this point please stop offering the trial to stage II patients, as we will then move to stage III randomisation only. However, please note that stage II patients that have already been offered the trial at this point may still be randomised.
Best wishes, Rachel Midgley
We are delighted to announce that the DATACAP trial has opened to recruitment at the Churchill Hospital, Oxford. The plan is to recruit 32 patients at this single site. We would like to thank all involved for their efforts so far.
Rachel Midgley and David Kerr
Click here for further details about the trial.
We are delighted to announce that FOXFIRE is now open to recruitment! Congratulations to Royal Surrey County Hospital for being the first site activated! We hope to open more sites very soon and would like to thank all involved for their efforts so far.
Rachel Midgley and David Kerr
Click here for further details about the trial.
Firstly a HUGE thank you for recruiting to this study over the last few years - it has been a long journey but one that we have enjoyed and we hope you have too! I think we all concede a certain disappointment in the results of C-08 presented at ASCO this year. However the results were tantalising and C-08 was different to QUASAR2: We remain the only study in the world to be testing Avastin in combination with single agent chemotherapy in the adjuvant setting of colorectal cancer. So QUASAR2 trial is of resounding importance in determining the role of anti-angiogenic therapy in this setting.
Because of the slightly slower, and therefore more prolonged, recruitment of QUASAR2 (and therefore increased chance of an event) fewer patients will be required to achieve the primary and secondary endpoints. Our statisticians have confirmed that we require a total of 1900 all-stage patients to achieve the primary endpoint of 3-year disease-free survival benefit in the overall population, with 90% power.
These numbers (about 200 in total to go) are expected to be achieved by the end of March 2010 if we recruit 50 patients per month. Can you help us do this? We think you can. Let's do it even faster. Let's get 1 patient per site per month and have it completed for Christmas!
Rachel Midgley and David Kerr
Further to the recent press release from Roche (see attached) re: the preliminary results of the C-08 trial of Avastin in the adjuvant treatment of colon cancer, we would like to confirm to our research community that we do not feel these results impact upon the continuing validity of or rationale for the QUASAR2 study. Indeed we believe that this result re-emphasises the importance of the QUASAR2 study. At the present time the results from the C-08 trial have not been released and are due to be presented at the ASCO meeting next month. However the trial tested the benefit of Avastin when added to a 5FU/oxaliplatin regime, which is significantly different to the question being asked in the QUASAR2 study, where we are assessing the effect of Avastin when added to single agent capecitabine. We are pleased to report that recruitment into QUASAR2 is going very well with today's recruitment figure standing at 1459 of a required total of 2240. We thank you wholeheartedly for your continuing support.
Rachel Midgley and David Kerr
Recruitment News COG now has 25 sites open to recruit patients however we still require more sites so please contact us if you're interested in setting up this exciting trial at your site. We will also be applying for the trial to be extended by an extra year.
Recruitment News
COG now has 25 sites open to recruit patients however we still require more sites so please contact us if you're interested in setting up this exciting trial at your site. We will also be applying for the trial to be extended by an extra year.
PPIs and Hip Fracture
Weighing up the evidence for risks and benefits of drug presciption is always difficult. Please click below for an American Journal of Gastroenterology paper by Paul Moayyedi about PPIs and hip fracture.
Click here to see full article.
Decision regarding the 2 randomisation time points:
"At the TSC meeting on 16th June 2009, the independent members of the committee came to a decision in relation to the 2 randomisation time points, based on the data presented in the first interim analysis report. The decision made was that the study should continue with the upfront randomisation time point only, for the rest of the duration of the study. This will be implemented on Monday 6th July 2009. Form this point onwards, all patients entered on to the study will be randomised upfront to either 12 or 24 weeks of treatment. This change will not affect sites currently randomising their patients upfront. All SCOT sites currently open to recruitment will be emailed as soon as possible with further details.
**Please also note that patients already registered to the study from sites currently on the delayed randomisation time point, these patients will still require to be randomised at week 12.**"
PPIs and Clopidogrel
Moayyedi and Sadowski have published an editorial about PPIs and Clopidogrel. You can download a PDF of the journal article here.
Please go to the AspECT restricted section for more guidelines and information relating to the management of AspECT patients.
We are delighted to announce that University Hospital of North Tees has been activated to recruit patients into EnROL.
Cancer Research UK have published a press release (29Apr2009) titled "Aspirin for forty somethings could cut cancer risk". This suggests that taking aspirin in your 40s could cut the risk of cancer developing later in life.
Click here to see full article
The number of CT scans mandated by the protocol is currently under review.
Click here for further details about the trial.
The EnROL Investigators Meeting will be held on the 1st July 2009 at the Goodenough College in London. All site staff involved with the trial are invited to attend this meeting.
AspECT recruitment phase is now closed having met and exceeded the recruitment target. Final number recruited is 2513 with a record 145 patients recruited during February.
We are pleased that University Hospital of North Tees has agreed to participate in the EnROL trial and is now in set up. We would like to welcome Mr Talvinder Gill and Alison Chilvers on board.
The AspECT recruitment period has been extended to 27 February 2009. There are only 138 patients left to recruit to reach our target of 2500.
AspECT is drawing to the end of its recruitment phase. In this last push to get the total recruitment to 2500, we need each site to recruit just 4 patients - i.e. 2 per month. This is easily achievable.
Please note that for drug resupply over Christmas and New Year, all orders must be placed by 19th Dec 2008 (17th Dec 208 for Northern Ireland). Normal service will resume on 05 Jan 2009.
Please do not send any samples from Friday 19 December 2008 until Friday 02 January 2009.
The DSMC met on 26th September 2008 and were optimistic about recruitment and could see no reason from a data and safety viewpoint for the trial not to continue.
EnROL has now 3 active sites and 3 patients recruited.
COG has received MHRA -CTA Approval and a Provisional Favourable Ethics Opinion, awaiting Final Approval. Site set-up is in progress.
We have been requested by the Sponsor of the study to highlight to all recruiting sites a recent protocol violation concerning the dose of capecitabine given to patients over the age of 70. The protocol states 'Patients >/= 70 years and or patients < 70 years with a creatinine clearance 30-50 mls/min will commence treatment with capecitabine at 75% of the full dose.' Please ensure this is checked and adhered to for all patients you are currently treating or will be treating in the future.
A presentation looking at recurrence rates in VICTOR patients according to COX-2 genotyping has been accepted for presentation at this year's ESMO conference in Stockholm (12-16 Sept 2008).
January 2008 saw what we hope will be the start of good things to come. 70 patients were randomised into the study besting our previous record of 51. A big 'thank you' goes out to everyone for their efforts.
We have now randomised over a third of our total patient target and we hope that this success can continue as we move into our last full year of recruitment.


text:
South Texas Botanical Gardens & Nature Center celebrates spring with "Big Bloom" festival
CORPUS CHRISTI - Spring is here, and that means love is in big bloom for plant lovers during the annual mega plant and garden festival at South Texas Botanical Gardens & Nature Center.
The Botanical Gardens will host its 15th annual "Big Bloom" sale — formerly known as the organization's spring plant sale — from 9 a.m. to 5 p.m. Saturday.
This year's sale will include orchid and plumeria, landscape plants and native plant and yard art vendors, as well as Xeriscape or water-wise plants, said MaryJane Crull, communications and marketing director for the Botanical Gardens.
"Due to the local drought restrictions, we are trying to encourage people to buy plants that are as water-safe as possible," said Crull, adding that Nueces Master Gardeners will be on site to answer shoppers' questions. "People will learn about what plants are right for their yard and how they can use different plants that are water-saving and yet still colorful."
It's Dollar Day at the festival, which means visitors can shop and tour the Botanical Gardens for only $1 per person thanks to corporate environmental sponsorships from Cheniere Energy, Citgo, Flint Hills Resources, H-E-B, Jason's Deli, NuStar Energy, the Port of Corpus Christi and City of Corpus Christi Solid Waste Services.
The event, which normally attracts about 3,000 visitors each year, also will offer free parking and feature a butterfly and ladybug release, reptile shows, visits with exotic parrots and afternoon music from local duo, Spark in the Dark. Plus, the kiddies can roam around the new Kids Tree House playground that sits on the trunk of a real 400-year old Oak tree.
"It's a great inexpensive family event," said Michael Womack, Botanical Gardens executive director and Caller-Times columnist. "There's more than just buying plants. It's a chance to have fun and experience nature."
Speaking of nature, visitors taking a stroll along the Botanical Gardens nature trail can enjoy two new bronze wildlife sculptures by world-renowned sculptor Kent Ullberg, and check out the center's reptile exhibit that includes rescued creatures donated to the facility.
Botanical Gardens members will be admitted free to start their shopping at 8 a.m. Members also will receive a 10 percent discount on plants and "Nature's Boutique" merchandise.
Susan Utter, a regular "Big Bloom" patron, has been attending the event for the past five years. She and her husband enjoy coming to the sale not only for the plants, but to glean home gardening tips from vendors, many of whom grow what they sell.
"It's really an attractive thing to talk to someone about buying a plant they've actually grown," said Utter, a Corpus Christi resident.
What: "Big Bloom" Plant Sale
Where: South Texas Botanical Gardens & Nature Center, 8545 S. Staples St.
When: 9 a.m. to 5 p.m. Saturday(Members only shopping from 8-9 a.m.)
Cost: $1
Information: 852-2100 or visit www.stxbot.org
8 a.m. Membership table opens
8-9 a.m. Members only shopping
9 a.m.-5 p.m. Big Bloom, Orchid Sale, vendors, Nature's Boutique, Tree House, Bounce House, Nueces Master Gardeners for Plant Questions
10:30 a.m. Lady Bug Release, Sensory Garden
11 a.m. Reptile Show, Eco-Fun Tent
Noon Butterfly Release, Butterfly House
Noon-3 p.m. Music by Spark in the Dark, Eco-Fun Tent
1-3 p.m. Parrots Galore/Companion Bird Club, Bromeliad House
1:30 p.m. Lady Bug Release, Hummingbird Garden
3 p.m. Reptile Show, Eco-Fun Tent
3:45 p.m. Lady Bug Release, Rose Garden
5 p.m. Big Bloom closes
Subscribe to the Caller-Times
Need Help? Call us at 1-800-566-8098.
Monday-Friday: 6am-3pm / Saturday: 7am-11am / Sunday: 7am-11am